» Articles » PMID: 7586896

The Role of Therapeutic Drug Monitoring in Improving the Cost Effectiveness of Anticonvulsant Therapy

Overview
Specialty Pharmacology
Date 1995 Jul 1
PMID 7586896
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

When monitoring of the plasma concentrations of anticonvulsant drugs first came into use 25 years ago, it appeared to have a major impact on improving the effectiveness and safety of anticonvulsant therapy. However, as time has passed, prescribers have absorbed many of the lessons to be learned from the monitoring, and now apply this knowledge without necessarily monitoring plasma anticonvulsant concentrations as frequently as in the past. Therefore, the effect of the drug concentration monitoring on the cost effectiveness of anticonvulsant therapy is probably not as significant now as it originally was. In theory, drug concentration monitoring is often unlikely to decrease the cost of contemporary anticonvulsant drug therapy, but it may enhance the efficacy of the therapy. Thus, monitoring may reveal unrecognised under- or overdosage, detect failure of compliance or drug-drug interactions, or indicate when there is little point in persisting with a particular anticonvulsant drug. Despite a good deal of anecdotal testimony, surprisingly little has been published demonstrating the benefits of anticonvulsant therapeutic drug monitoring in epileptic populations. However, one study did show better rates of seizure control rates in patients monitored in the first 6 months of their epileptic disorder; but not if the monitoring began later than this.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Jaquenoud Sirot E, van der Velden J, Rentsch K, Eap C, Baumann P Drug Saf. 2006; 29(9):735-68.

PMID: 16944962 DOI: 10.2165/00002018-200629090-00001.


A pharmacoeconomic analysis of the impact of therapeutic drug monitoring in adult patients with generalized tonic-clonic epilepsy.

Rane C, Dalvi S, Gogtay N, Shah P, Kshirsagar N Br J Clin Pharmacol. 2001; 52(2):193-5.

PMID: 11488777 PMC: 2014520. DOI: 10.1046/j.0306-5251.2001.01436.x.


Therapeutic drug monitoring: do the improved outcomes justify the costs?.

Schumacher G, Barr J Clin Pharmacokinet. 2001; 40(6):405-9.

PMID: 11475466 DOI: 10.2165/00003088-200140060-00002.


Is there a role for therapeutic drug monitoring of new anticonvulsants?.

Perucca E Clin Pharmacokinet. 2000; 38(3):191-204.

PMID: 10749516 DOI: 10.2165/00003088-200038030-00001.


Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants.

Liu H, Delgado M Clin Pharmacokinet. 1999; 36(6):453-70.

PMID: 10427469 DOI: 10.2165/00003088-199936060-00006.


References
1.
LEVY L, Fenichel G . DIPHENYLHYDANTOIN ACTIVATED SEIZURES. Neurology. 1965; 15:716-22. DOI: 10.1212/wnl.15.8.719. View

2.
BUCHTHAL F, SVENSMARK O, SCHILLER P . Clinical and electroencephalographic correlations with serum levels of diphenylhydanotin. Arch Neurol. 1960; 2:624-30. DOI: 10.1001/archneur.1960.03840120030004. View

3.
Naestoft J, Lund M, Larsen N, HVIDBERG E . Assay and pharmacokinetics of clonazepam in humans. Acta Neurol Scand Suppl. 1973; 53:103-8. DOI: 10.1111/j.1600-0404.1973.tb02292.x. View

4.
Peterson G, McLean S, MILLINGEN K . A randomised trial of strategies to improve patient compliance with anticonvulsant therapy. Epilepsia. 1984; 25(4):412-7. DOI: 10.1111/j.1528-1157.1984.tb03436.x. View

5.
Jeavons P, Clark J, Maheshwari M . Treatment of generalized epilepsies of childhood and adolescence with sodium valproate ("epilim"). Dev Med Child Neurol. 1977; 19(1):9-25. DOI: 10.1111/j.1469-8749.1977.tb08015.x. View